FDA grants accelerated approval to first targeted treatment for rare Duchenne muscular dystrophy mutation
- Details
- Category: FDA
![FDA FDA](/images/logo/fda.png)
FDA launches app for health care professionals
- Details
- Category: FDA
![FDA FDA](/images/logo/fda.png)
FDA approves first generics of Gilenya
- Details
- Category: FDA
![FDA FDA](/images/logo/fda.png)
MS is a chronic, inflammatory, autoimmune disease of the central nervous system that disrupts communication between the brain and other parts of the body.
FDA approves novel treatment to target abnormality in sickle cell disease
- Details
- Category: FDA
![FDA FDA](/images/logo/fda.png)
"Today's approval provides additional hope to the 100,000 people in the U.S., and the more than 20 million globally, who live with this debilitating blood disorder," said Acting FDA Commissioner Adm. Brett P. Giroir, M.D.
FDA approves first treatment for inherited rare disease
- Details
- Category: FDA
![FDA FDA](/images/logo/fda.png)
FDA approves first targeted therapy to treat patients with painful complication of sickle cell disease
- Details
- Category: FDA
![FDA FDA](/images/logo/fda.png)
FDA approves first therapy to treat patients with rare blood disorder
- Details
- Category: FDA
![FDA FDA](/images/logo/fda.png)
More Pharma News ...
- Digital submission of adverse event reports for investigational new drug applications
- First vaccine to protect against Ebola
- FDA approves new treatment for patients with migraine
- FDA awards 12 grants to fund new clinical trials to advance the development of medical products for the treatment of rare diseases
- FDA approves second drug to prevent HIV infection as part of ongoing efforts to end the HIV epidemic
- FDA announces voluntary recall of Sandoz ranitidine capsules following detection of an impurity
- FDA approves first oral GLP-1 treatment for type 2 diabetes